Fluidigm Co. (NASDAQ:FLDM) – Research analysts at Piper Jaffray Companies upped their Q1 2019 earnings per share estimates for Fluidigm in a research report issued to clients and investors on Tuesday, March 12th. Piper Jaffray Companies analyst W. Quirk now anticipates that the medical research company will post earnings per share of ($0.10) for the quarter, up from their previous forecast of ($0.17). Piper Jaffray Companies currently has a “Overweight” rating and a $14.00 target price on the stock. Piper Jaffray Companies also issued estimates for Fluidigm’s Q2 2019 earnings at ($0.09) EPS, Q3 2019 earnings at ($0.09) EPS, Q4 2019 earnings at ($0.08) EPS and FY2019 earnings at ($0.36) EPS.

Fluidigm (NASDAQ:FLDM) last posted its earnings results on Thursday, February 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 90.07%. The business had revenue of $32.33 million for the quarter, compared to analyst estimates of $30.55 million.

A number of other research analysts have also issued reports on the stock. UBS Group began coverage on shares of Fluidigm in a research note on Friday. They issued a “neutral” rating on the stock. BTIG Research began coverage on shares of Fluidigm in a research note on Wednesday. They issued a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research upgraded shares of Fluidigm from a “strong sell” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, March 5th. BidaskClub upgraded shares of Fluidigm from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. Finally, Janney Montgomery Scott upgraded shares of Fluidigm from a “neutral” rating to a “buy” rating in a research note on Thursday, January 3rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Fluidigm has a consensus rating of “Buy” and an average target price of $14.00.

NASDAQ:FLDM opened at $13.81 on Friday. Fluidigm has a 1 year low of $4.65 and a 1 year high of $14.50. The company has a current ratio of 1.85, a quick ratio of 1.45 and a debt-to-equity ratio of 7.56. The firm has a market capitalization of $551.27 million, a P/E ratio of -17.26 and a beta of 2.40.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Primecap Management Co. CA grew its position in Fluidigm by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 5,856,043 shares of the medical research company’s stock worth $43,862,000 after purchasing an additional 64,000 shares during the last quarter. Neuberger Berman Group LLC grew its position in Fluidigm by 0.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 4,535,180 shares of the medical research company’s stock worth $33,971,000 after purchasing an additional 24,186 shares during the last quarter. Renaissance Technologies LLC grew its position in Fluidigm by 7.7% in the 3rd quarter. Renaissance Technologies LLC now owns 1,152,800 shares of the medical research company’s stock worth $8,634,000 after purchasing an additional 82,300 shares during the last quarter. Algert Global LLC acquired a new stake in Fluidigm in the 4th quarter worth $483,000. Finally, JPMorgan Chase & Co. grew its position in Fluidigm by 739.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 72,339 shares of the medical research company’s stock worth $542,000 after purchasing an additional 63,721 shares during the last quarter.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Read More: Technical Analysis

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.